When was Abdera Therapeutics founded?

Abdera Therapeutics was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Abdera Therapeutics located?

Abdera Therapeutics is headquartered in Vancouver, Canada. It is registered at Suite 2600, Three Bentall Centre, Vancouver.

Who is the current CEO of Abdera Therapeutics?

Lori Lyons-Williams of Abdera Therapeutics.

How many employees does Abdera Therapeutics have?

As of Mar 31, 2026, the latest employee count at Abdera Therapeutics is 68.

Is Abdera Therapeutics a funded company?

Abdera Therapeutics is a funded company, having raised a total of $149M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 14, 2021.

When was the latest funding round of Abdera Therapeutics?

Abdera Therapeutics' latest funding was a $***** Series B round on Apr 20, 2023, with participation from 8 investors.

Where does Abdera Therapeutics rank among its competitors?

Abdera Therapeutics ranks 82nd amongst 2467 active competitors, of which 859 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Erasca, which secured $45M in Mar, 2024.

Abdera Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Q: Who are the top competitors of Abdera Therapeutics?

Abdera Therapeutics' top competitors include Jazz Pharmaceuticals, Advanced Accelerator Applications and Sana Biotechnology. Among them, Erasca secured the most recent funding round in March, 2024.

Company Details

Provider of therapeutics for cancer treatment. It has ROVEr platform which integrates antibody engineering with radionuclide payloads aiming to deliver either alpha- or beta-emitting radioisotopes selectively to tumour cells. It offers a lead clinical program is ABD 147 for small cell lung cancer and large cell neuroendocrine carcinoma, and ABD 320 targeting multiple cancer types.

Website: abderatx.com
Social
Email ID: *****@abderatx.com
Phone Number: +1 **********
Registered Address: Suite 2600, Three Bentall Centre, Vancouver

Key Metrics

Founded Year

2020

Location

Vancouver, Canada

Stage

Series B

Total Funding

$149M in 3 rounds

Latest Funding Round

Series B, Apr 20, 2023, $*****

Investors

Versant Ventures & 8 more

Ranked

82^nd among 2467 active competitors

Employee Count

68 as on Mar 31, 2026

Similar Companies

Advanced Accelerator Applications & 86 more

View Abdera Therapeutics' full profile

Abdera Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Abdera Therapeutics Inc. CIN: 12551331 , Canada, Active	Dec 07, 2020	-	-	-

Abdera Therapeutics has raised a total funding of $149M over 3 rounds. Its first funding round was on Jan 14, 2021. Its latest funding round was a Series B round on Apr 20, 2023 for $*****. 8 investors participated in its latest round. Abdera Therapeutics has 9 institutional investors.

Here is the list of recent funding rounds of Abdera Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 20, 2023	3298315	Series B	4392724	2581120	3948129	4595013
2021	1928	Series A	6956	7579	6818	Abcellera Biologics & 2 more
Jan 14, 2021	8545077	Seed	4112192	9573057	8660040	3659971

Access funding benchmarks and valuations. Sign up today!

View details of Abdera Therapeutics's funding rounds and investors

The founders of Abdera Therapeutics are Adam Judge, Lana Janes and Mike Abrams. Lori Lyons-Williams is the CEO of Abdera Therapeutics.

Here are the details of Abdera Therapeutics' key team members:

Adam Judge: Co-Founder of Abdera Therapeutics.
Contact Info: 1 email address
Lana Janes: Co-Founder of Abdera Therapeutics.
Mike Abrams: Co-Founder and Sr. Advisor of Abdera Therapeutics.
Lori Lyons-Williams: President and CEO of Abdera Therapeutics.

View details of Abdera Therapeutics's Founder profiles and Board Members

Abdera Therapeutics' employee count trend

Abdera Therapeutics has 68 employees as of Mar 26. Here is Abdera Therapeutics's employee count trend over the years:

Employee count trend for Abdera Therapeutics

Uncover Abdera Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Abdera Therapeutics include Jazz Pharmaceuticals, Advanced Accelerator Applications and Sana Biotechnology. Here is the list of Top 10 competitors of Abdera Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Vivo Capital, Tamburi Investment Partners ... & 4 others	78/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Baillie Gifford & 17 others	75/100
4th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
5th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Redmile Group, Fidelity Investments & 28 others	72/100
8th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	71/100
9th	iTeos Therapeutics 2011, Cambridge (United States), Acquired	Developer of immunotherapy for treating cancer	$204M	Boxer Capital, RA Capital Management & 19 others	70/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Arch Venture Partners, Cormorant Asset Management ... & 13 others	70/100
82nd	Abdera Therapeutics 2020, Vancouver (Canada), Series B	Provider of therapeutics for cancer treatment.	$149M	RTW Investments, Viking Global Investors & 7 others	63/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Abdera Therapeutics's competitors? Click here to see the top ones

Abdera Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Abdera Therapeutics's sector:

Free

Oncology - Sector Report

Edition: October, 2025 (81 Pages)

View all reports related to Abdera Therapeutics

Media has covered Abdera Therapeutics for a total of 4 events in the last 1 year, 2 of them have been about company updates and 1 about people movement.